

**REMARKS**

*Sequence Listing:*

Enclosed herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a Substitute Sequence Listing to be inserted into the specification as indicated above. The Substitute Sequence Listing in no way introduces new matter into the specification. Also submitted herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a disk copy of the Substitute Sequence Listing. The disk copy of the Substitute Sequence Listing, file "2003-04-07 1254-0191P.st25.txt", is identical to the paper copy, except that it lacks formatting.

The Substitute Sequence Listing corrects the errors relating to place holders SEQ ID NOS: 179 and 180 as outlined in the "raw sequence listing error report" dated March 11, 2003. No new matter is introduced by these amendments.

*Figures:*

The present application was filed without any figures. However, this application incorporated by reference provisional application no. 60/314,385 which contained figure 1 that is attached hereto. Applicants request that this figure 1 be made part of the present application by way of this amendment. Because this figure was first incorporated by reference through application no. 60/314,385 at the time of filing, no new matter is introduced by the addition of this figure.


This amendment changes the figure descriptions in the specification to reflect the addition of figure 1. The added figure description was originally filed in provisional application no. 60/314,385 to which the present application incorporates by reference. No new matter is being added by the amended figure description.

Application No. 10/024,298

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
Gerald M. Murphy, Jr., Reg. No. 28,977

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

*BCF/cw*  
GMM/BCF

Attachments:

Disk Copy of Sequence Listing  
Paper Copy of Sequence Listing  
Figure 1  
Copy of Notice  
Version with markings

(Rev. 03/27/01)

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

The paragraph beginning on page 11 line 7 and ending on page 13 line 11:

Fig. 1 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 5) in Example 3, the axis of abscissa is MG-132 concentration and the transversal axis is relative luciferase activity where relative luciferase activity is taken as 100% under conditions of non-addition of MG-132 (0  $\mu$ M). (Relative luciferase activity at various concentrations was divided by relative luciferase activity under conditions of non-addition of MG-132, and expressed as a percentage.)

Fig. 2 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 9) in Example 3.

Fig. 3 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 17) in Example 3.

Fig. 4 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 21) in Example 3.

Fig. 5 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 35) in Example 3.

Fig. 6 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 37) in Example 3.

Fig. 7 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 41) in Example 3.

Fig. 8 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 53) in Example 3.

Fig. 9 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 57) in Example 3.

Fig. 10 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 63) in Example 3.

Fig. 11 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 67) in Example 3.

Fig. 12 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 71) in Example 3.

Fig. 13 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 75) in Example 3.

Fig. 14 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 81) in Example 3.

Fig. 15 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 87) in Example 3.

Fig. 16 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 91) in Example 3.

Fig. 17 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 93) in Example 3.

Fig. 18 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 97) in Example 3.

Fig. 19 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 121) in Example 3.

Fig. 20 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 123) in Example 3.

Fig. 21 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 129) in Example 3.

Fig. 22 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 154) in Example 3.

Fig. 23 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 158) in Example 3.

Fig. 24 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 162) in Example 3.

Fig. 25 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 168) in Example 3.

Fig. 26 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 170) in Example 3.

Fig. 27 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 172) in Example 3.

Fig. 28 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 176) in Example 3.

Fig. 29 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG-132 (SEQ ID NO: 178) in Example 3.

Fig. 1 is a graph showing NF- $\kappa$ B reporter activity inhibition by the proteasome inhibitor MG132 in Example 3, the axis of abscissa is MG132 concentration and the transversal axis is relative luciferase activity.